Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.

Ann Rheum Dis · 2022 · PMC8995831 · PMID 35193872

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While there was a trend towards better structural efficacy in patients with higher disease activity states also with baricitinib monotherapy compared with MTX monotherapy, this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.